Literature DB >> 34340978

Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli et al.

Caoilfhionn Marie Connolly1, Darya Koenig2, Srekar N Ravi3, Antoine Azar2, Sam Kant4, Monika Dalal1, Jessica Duchen5, Philip Seo1, Brendan Antiochos1, Julie J Paik1, Duvuru Geetha6,4.   

Abstract

Entities:  

Keywords:  Covid-19; rituximab; systemic vasculitis; vaccination

Mesh：

Substances：

Year:  2021        PMID： 34340978     DOI： 10.1136/annrheumdis-2021-220972

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   27.973


× No keyword cloud information.
  6 in total

1.  Predictors of Immunogenic Response to the BNT162b2 mRNA COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases Treated with Rituximab.

Authors:  Victoria Furer; Tali Eviatar; Devy Zisman; Hagit Peleg; Yolanda Braun-Moscovici; Alexandra Balbir-Gurman; Daphna Paran; David Levartovsky; Michael Zisapel; Ofir Elalouf; Ilana Kaufman; Adi Broyde; Ari Polachek; Joy Feld; Amir Haddad; Tal Gazitt; Muna Elias; Nizar Higazi; Fadi Kharouf; Sara Pel; Sharon Nevo; Ori Elkayam
Journal:  Vaccines (Basel)       Date:  2022-06-06

2.  The Risk of Severe Infections Following Rituximab Administration in Patients With Autoimmune Kidney Diseases: Austrian ABCDE Registry Analysis.

Authors:  Balazs Odler; Martin Windpessl; Marcell Krall; Maria Steiner; Regina Riedl; Carina Hebesberger; Martin Ursli; Emanuel Zitt; Karl Lhotta; Marlies Antlanger; Daniel Cejka; Philipp Gauckler; Martin Wiesholzer; Marcus Saemann; Alexander R Rosenkranz; Kathrin Eller; Andreas Kronbichler
Journal:  Front Immunol       Date:  2021-10-29       Impact factor: 7.561

3.  SARS-CoV-2 Vaccine Response in Patients With Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis.

Authors:  Lauren Floyd; Mohamed E Elsayed; Tobias Seibt; Anke von Bergwelt-Baildon; Philip Seo; Brendan Antiochos; Sam Kant; Adam Morris; Ajay Dhaygude; Ulf Schönermarck; Duvuru Geetha
Journal:  Kidney Int Rep       Date:  2021-12-11

4.  COVID-19 mRNA Vaccine in Patients With Lymphoid Malignancy or Anti-CD20 Antibody Therapy: A Systematic Review and Meta-Analysis.

Authors:  Yusuke Ito; Akira Honda; Mineo Kurokawa
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2022-03-28

5.  Antibody Response to mRNA Vaccines against SARS-CoV-2 with Chronic Kidney Disease, Hemodialysis, and after Kidney Transplantation.

Authors:  Lukas Buchwinkler; Claire Anne Solagna; Janosch Messner; Markus Pirklbauer; Michael Rudnicki; Gert Mayer; Julia Kerschbaum
Journal:  J Clin Med       Date:  2021-12-28       Impact factor: 4.241

6.  Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS.

Authors:  Kate I Stevens; Eleni Frangou; Jae I L Shin; Hans-Joachim Anders; Annette Bruchfeld; Ulf Schönermarck; Thomas Hauser; Kerstin Westman; Gema M Fernandez-Juarez; Jürgen Floege; Dimitrios Goumenos; Kultigin Turkmen; Cees van Kooten; Stephen P McAdoo; Vladimir Tesar; Mårten Segelmark; Duvuru Geetha; David R W Jayne; Andreas Kronbichler
Journal:  Nephrol Dial Transplant       Date:  2022-07-26       Impact factor: 7.186
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.